{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.18556"}, {"@name": "filename", "#text": "25550_RMM.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "UNIVERSIDADE DE S\u00c3O PAULO \n\nFACULDADE DE CI\u00caNCIAS FARMAC\u00caUTICAS DE RIBEIR\u00c3O PRETO \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDesenvolvimento de dispers\u00f5es s\u00f3lidas microparticuladas \n\ncontendo carbamazepina por spray congealing \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nRodrigo Molina Martins \n\n \n\n \n\n \n\n \n\n \n\n \n\nRibeir\u00e3o Preto \n\n2010 \n\n\n\n \n\n  \n\n5\n\nUNIVERSIDADE DE S\u00c3O PAULO \n\nFACULDADE DE CI\u00caNCIAS FARMAC\u00caUTICAS DE RIBEIR\u00c3O PRETO \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDesenvolvimento de dispers\u00f5es s\u00f3lidas microparticuladas \n\ncontendo carbamazepina por spray congealing \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nRibeir\u00e3o Preto \n\n2010 \n\n \n \n \nDisserta\u00e7\u00e3o de Mestrado apresentada ao Programa de \nP\u00f3s-Gradua\u00e7\u00e3o em Ci\u00eancias Farmac\u00eauticas para \nobten\u00e7\u00e3o do T\u00edtulo de Mestre em Ci\u00eancias. \n\n \n\u00c1rea de Concentra\u00e7\u00e3o: Medicamentos e Cosm\u00e9ticos. \n\n \nOrientado: Rodrigo Molina Martins \nOrientador: Prof. Dr. Luis Alexandre Pedro de Freitas \n\n\n\n \n\n  \n\n6\n\nAUTORIZO A REPRODU\u00c7\u00c3O E DIVULGA\u00c7\u00c3O TOTAL OU PARCIAL DESTE \nTRABALHO, POR QUALQUER MEIO CONVENCIONAL OU ELETR\u00d4NICO, \nPARA FINS DE ESTUDO E PESQUISA, DESDE QUE CITADA A FONTE. \n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \nMartins, Rodrigo Molina \n\nDesenvolvimento de dispers\u00f5es s\u00f3lidas microparticuladas contendo \ncarbamazepina por spray congealing. \n\n166 p.: Il.;; 30cm. \n \n\nDisserta\u00e7\u00e3o de Mestrado, apresentada \u00e0 Faculdade de Ci\u00eancias \n\nFarmac\u00eauticas de Ribeir\u00e3o Preto/USP \u2013 \u00c1rea de concentra\u00e7\u00e3o: \n\nMedicamentos e Cosm\u00e9ticos \n\nOrientador: Freitas, Luis Alexandre Pedro de \n \n\n       1. spray congealing. 2. dispers\u00e3o s\u00f3lida 3. carbamazepina 4. \nmicropart\u00edculas 5. planejamento experimental \n\n \n\n \n \n\n\n\n \n\n  \n\n7\n\nRESUMO \n \n\nMARTINS, R. M. Desenvolvimento de dispers\u00f5es s\u00f3lidas microparticuladas \ncontendo carbamazepina por spray congealing. 2010. 166f. Disserta\u00e7\u00e3o \n(Mestrado). Faculdade de Ci\u00eancias Farmac\u00eauticas de Ribeir\u00e3o Preto \u2013 Universidade \nde S\u00e3o Paulo, Ribeir\u00e3o Preto, 2010. \n\n \nO melhoramento das propriedades de dissolu\u00e7\u00e3o de produtos farmac\u00eauticos \u00e9 \nextremamente importante, visto que houve um aumento de f\u00e1rmacos de baixa \nsolubilidade disponibilizados no mercado farmac\u00eautico nos \u00faltimos tempos. V\u00e1rias \nt\u00e9cnicas t\u00eam sido utilizadas para melhorar as propriedades de dissolu\u00e7\u00e3o destes \nf\u00e1rmacos como a cominui\u00e7\u00e3o, o uso de surfactantes e o preparo de dispers\u00f5es \ns\u00f3lidas. A prepara\u00e7\u00e3o de dispers\u00f5es s\u00f3lidas \u00e9 um m\u00e9todo \u00fatil para dispersar mol\u00e9culas \nde f\u00e1rmaco em uma matriz s\u00f3lida hidrof\u00edlica. A t\u00e9cnica de spray congealing \u00e9 usada \npara produ\u00e7\u00e3o de micropart\u00edculas n\u00e3o necessitando de solventes org\u00e2nicos ou \naquosos. O presente trabalho teve o objetivo de produzir micropart\u00edculas de dispers\u00e3o \ns\u00f3lida contendo carbamazepina (CBZ) preparadas por spray congealing e estudar a \ninflu\u00eancia dos par\u00e2metros do processo. A CBZ foi usada como f\u00e1rmaco modelo por \napresentar baixa solubilidade e ser o medicamento de primeira escolha no tratamento \nda epilepsia psicomotora. Inicialmente foram preparadas dispers\u00f5es s\u00f3lidas usando \ncomo carreador o polioxilglicer\u00eddeo (Gelucire\u00ae 50/13), e os polietilenoglic\u00f3is (PEG \n4000 e PEG 6000) nas propor\u00e7\u00f5es 1:9, 1:5 e 1:1 (f\u00e1rmaco:carreador), pelo m\u00e9todo da \nfus\u00e3o e posteriormente submetidas a estudos de solubilidade, onde a dispers\u00e3o s\u00f3lida \ncom Gelucire\u00ae 50/13 (1:9) mostrou melhor solubilidade em rela\u00e7\u00e3o a CBZ pura, sendo \nselecionada para o processo de produ\u00e7\u00e3o de microparticulados por spray congealing. \nAs micropart\u00edculas foram obtidas utilizando um planejamento experimental do tipo Box-\nBehnken, estudando os seguintes par\u00e2metros: vaz\u00e3o de dispers\u00e3o, vaz\u00e3o do ar de \nresfriamento e press\u00e3o de atomiza\u00e7\u00e3o num total de 15 experimentos. Os \nmicroparticulados foram caracterizados pelos estudos de tamanho de part\u00edcula, \ndensidade aparente, densidade compactada, fator de Hausner, \u00edndice de Carr, \u00e2ngulo \nde repouso, efici\u00eancia de encapsula\u00e7\u00e3o, atividade de \u00e1gua, solubilidade, teor de \numidade e rendimento do processo, sendo todas estas propriedades avaliadas pela \nt\u00e9cnica de superf\u00edcie de resposta (ANOVA). A an\u00e1lise estat\u00edstica demonstrou que o \nrendimento sofreu influ\u00eancia das tr\u00eas vari\u00e1veis enquanto que o teor de umidade foi \ndependente apenas da vaz\u00e3o de dispers\u00e3o. As demais propriedades n\u00e3o sofreram \ninflu\u00eancia significante dos par\u00e2metros estudados. A dispers\u00e3o s\u00f3lida, a mistura f\u00edsica e \nas micropart\u00edculas de CBZ em Gelucire\u00ae 50/13 tiveram suas caracter\u00edsticas f\u00edsico-\nqu\u00edmicas avaliadas por difra\u00e7\u00e3o de raios-x, espectroscopia em infravermelho, \nmicroscopia de plataforma a quente e an\u00e1lises t\u00e9rmicas (DSC e TG). Os resultados \ndas an\u00e1lises mostraram que n\u00e3o ocorreram intera\u00e7\u00f5es f\u00edsico-qu\u00edmicas entre o f\u00e1rmaco \ne o carreador. No entanto, o processo de preparo da dispers\u00e3o conduziu uma \nmudan\u00e7a no estado cristalino da CBZ convertendo parcialmente a forma polim\u00f3rfica III \npara uma forma I. Os microparticulados apresentaram fluxo de bom a moderado com \nbons rendimentos (50-80 %), baixo teor de umidade (&lt;2%), atividade de \u00e1gua menor \nque 0,550 e boa efici\u00eancia de encapsula\u00e7\u00e3o (99,5 a 112 %). O tamanho m\u00e9dio das \nmicropart\u00edculas variou de 53,09 a 78,75 \u00b5m.e sua morfologia analisada por \nmicroscopia eletr\u00f4nica de varredura mostrou forma esf\u00e9rica, superf\u00edcie lisa com \nalgumas irregularidades e aparentemente n\u00e3o porosa. A solubilidade da CBZ contida \nnas micropart\u00edculas apresentou um aumento de 2,70 vezes em rela\u00e7\u00e3o ao f\u00e1rmaco \npuro. As caracter\u00edsticas do estado s\u00f3lido das micropart\u00edculas foram semelhantes \u00e0s da \ndispers\u00e3o s\u00f3lida. As micropart\u00edculas estudadas conduziram a um aumento na taxa de \ndissolu\u00e7\u00e3o in vitro da CBZ comparada a sua respectiva dispers\u00e3o s\u00f3lida e a CBZ pura. \nPortanto, o spray congealing, \u00e9 um m\u00e9todo promissor para ser empregado e \ndesenvolvido na fabrica\u00e7\u00e3o de micropart\u00edculas de f\u00e1rmacos pouco sol\u00faveis. \n \nPalavras-chaves: carbamazepina, dispers\u00e3o s\u00f3lida, spray congealing, micropart\u00edculas. \n\n \n\n\n\n \n\n  \n\n8\n\nABSTRACT \n\n \n\nMARTINS, R. M. Development of carbamazepine microparticulated solid \ndispersions by spray congealing. 2010. 166f. Disserta\u00e7\u00e3o (Mestrado). Faculdade de \nCi\u00eancias Farmac\u00eauticas de Ribeir\u00e3o Preto \u2013 Universidade de S\u00e3o Paulo, Ribeir\u00e3o \nPreto, 2010. \n \nImprovement of dissolution properties of pharmaceutical products is extremely \nimportant, especially because the percentage of poor water soluble drugs has \nincreased in the pharmaceutical market lately. Several techniques have been used to \nimprove the dissolution properties of drugs such as grinding, the use of surfactants and \npreparation of solid dispersions. The preparation of solid dispersions is a useful method \nfor disperse the drug molecules in a hydrophilic solid matrix. The spray congealing \ntechnique is used for production of microparticles and do not require organic or \naqueous solvents. This work aimed to produce microparticles of solid dispersion \nprepared by spray congealing and to study the influence of process parameters. \nCarbamazepine (CBZ) was used as model drug due to its poor solubility and because it \nis the first choice drug for the treatment of psychomotor epilepsy. Initially solid \ndispersions were prepared using as carriers polyoxylglyceride (Gelucire\u00ae 50/13), and \npolyethylene glycols (PEG 4000 and PEG 6000) in the proportions 1:9, 1:5 and 1:1 \n(drug: carrier), applying the hot melt method .Solid dispersion with Gelucire \u00ae 50/13 \n(1:9) showed better solubility compared to pure CBZ, being selected for the further \nproduction of microparticles by spray congealing. The microparticles were obtained \nusing a Box Behnken experimental design, studying the following parameters: flow rate \nof liquid dispersion, flow rate of cooling air and atomizing pressure for a total of 15 \nexperiments. The microparticles were characterized by studies of particle size, bulk \ndensity, compacted density, Hausner factor, Carr index, angle of repose, encapsulation \nefficiency, water activity, solubility, moisture content and yield of the process. These \neffects were analyzed by response surface technique (ANOVA). Statistical analysis \nshowed that the yield was influenced by all three variables while the moisture was only \ndependent on the flow dispersion. The other properties were not significantly influenced \nby the parameters. The solid dispersion, physical mixture and microparticles of CBZ in \nGelucire\u00ae 50/13 had their physical and chemical characteristics evaluated by x-ray \ndiffraction, infrared spectroscopy, hot stage microscopy and thermal analysis (DSC and \nTG). The analysis of the results showed that there were no physical-chemical \ninteractions between the drug and carrier. However, the preparation process of \ndispersion has led to a change in the crystalline state of CBZ, partially converting the \npolymorphic form III to the polymorphic form I. The microparticles showed good to \nmoderate flow and good yields (50-80%), low moisture content (<2%), water activity \nlowerless than 0.550 and good encapsulation efficiency (99.5 to 112%) The average \nsize microparticles ranged from 53.09 to 78.75 ?m. The morphology was analyzed by \nscanning electron microscopy and showed spherical shape, smooth surface with minor \nirregularities and apparently non-porous. The solubility of CBZ in the microparticles \nshowed an increase of 2.70 times the solubility CBZ alone. The characteristics of \nmicroparticulated solid dispersions were similar to that of the solid dispersion. The \nmicroparticles studied led to an increase in dissolution rate of CBZ in vitro compared to \nits corresponding solid dispersion and pure CBZ. Therefore, the spray congealing is a \npromising method to be developed and employed in the manufacture of microparticles \nof poorly soluble drugs. \n \nKeywords: carbamazepine solid dispersion, spray congealing, microparticles.  \n \n \n \n\n\n\n \n\n  \n\n9\n\n1 INTRODU\u00c7\u00c3O \n\n O interesse em melhorar as propriedades de dissolu\u00e7\u00e3o de ingredientes \n\nativos farmac\u00eauticos (IAF) tem crescido significativamente nos \u00faltimos anos em \n\nvirtude da demanda de f\u00e1rmacos pouco sol\u00faveis no mercado farmac\u00eautico nos \n\n\u00faltimos anos (SHARMA et al, 2009). F\u00e1rmacos pouco sol\u00faveis representam um \n\nproblema por apresentarem baixas biodisponibilidade e taxa de dissolu\u00e7\u00e3o \n\n(FINI et al., 2005). Portanto, al\u00e9m da permeabilidade, a solubilidade e a \n\ndissolu\u00e7\u00e3o de um f\u00e1rmaco s\u00e3o par\u00e2metros fundamentais para sua \n\nbiodisponibilidade oral (CAVALLARI et al., 2007). Junto com a microniza\u00e7\u00e3o, \n\noutros m\u00e9todos t\u00eam sido propostos para aumentar a taxa de dissolu\u00e7\u00e3o de IAF, \n\ntais como a produ\u00e7\u00e3o de sais ou complexos sol\u00faveis, o uso de surfactantes e a \n\nprepara\u00e7\u00e3o de dispers\u00f5es s\u00f3lidas (FINI et al., 2002). \n\nO termo dispers\u00e3o s\u00f3lida tem sido utilizado para descrever formas \n\nfarmac\u00eauticas em que o f\u00e1rmaco \u00e9 disperso em uma matriz biologicamente \n\ninerte, geralmente com o prop\u00f3sito de aumentar a biodisponibilidade oral. \n\nChiou e Riegelman (1971) definem esse sistema como a dispers\u00e3o de um ou \n\nmais ingredientes ativos em uma matriz inerte fundida. Com isto, a libera\u00e7\u00e3o in \n\nvitro \u00e9 aumentada quando comparada a formas farmac\u00eauticas convencionais. \n\nOs tipos de matrizes utilizados na prepara\u00e7\u00e3o de dispers\u00f5es s\u00f3lidas s\u00e3o \n\nconstitu\u00eddos por pol\u00edmeros hidrof\u00edlicos como polietilenoglicol (PEG), \n\npolivinilpirrolidona (PVP) e mat\u00e9rias de baixo peso molecular como a\u00e7\u00facares ou \n\nexcipientes lipof\u00edlicos (ceras e lip\u00eddios) (CRAIG, 2002; SAVOLAINEN et al., \n\n2002). Apesar de intensamente pesquisada, a aplica\u00e7\u00e3o de dispers\u00f5es s\u00f3lidas \n\nem produtos farmac\u00eauticos \u00e9 limitada. A raz\u00e3o para isso pode ser devida a \n\nproblemas com o m\u00e9todo de prepara\u00e7\u00e3o, reprodutibilidade relacionada \u00e0s \n\npropriedades f\u00edsico-qu\u00edmicas de formas farmac\u00eauticas, transposi\u00e7\u00e3o de escala \n\ndo m\u00e9todo de produ\u00e7\u00e3o e/ou estabilidade (SERAJUDDIN, 1999; \n\nBREITENBACH, 2002). Uma das alternativas para superar esses obst\u00e1culos \n\nseria o emprego de t\u00e9cnicas, como por exemplo, a tecnologia de \n\nmicroencapsula\u00e7\u00e3o, que auxilia na obten\u00e7\u00e3o de formas farmac\u00eauticas a partir \n\nde dispers\u00f5es s\u00f3lidas, e garante uma maior homogeneidade do produto final. \n\n A microencapsula\u00e7\u00e3o \u00e9 uma tecnologia que consiste na aplica\u00e7\u00e3o de um \n\nrevestimento relativamente fino a pequenas part\u00edculas de s\u00f3lidos, got\u00edculas \n\nl\u00edquidas ou quantidades de g\u00e1s (na faixa de 1 a 1000 ?m) promovendo uma \n\n\n\n \n\n  \n\n10\n\nprote\u00e7\u00e3o completa ou parcial destas subst\u00e2ncias (CHAMBI; ALVIM; BARRERA-\n\nARELLANO, 2007. O emprego desses sistemas possibilita o mascaramento \n\ndos sabores e dos odores indesej\u00e1veis eventualmente apresentados pelo \n\nprinc\u00edpio ativo, podendo tamb\u00e9m proteg\u00ea-lo de fatores ambientais ou dos riscos \n\nproporcionados pelo pr\u00f3prio material encapsulado. P\u00f3s muito finos podem ser \n\nencapsulados para evitar que se aglomerem e os produtos podem ter sua \n\ndensidade modificada por esse processo. Al\u00e9m disso, uma aplica\u00e7\u00e3o de grande \n\nimport\u00e2ncia das micropart\u00edculas na \u00e1rea farmac\u00eautica consiste na modula\u00e7\u00e3o \n\nda libera\u00e7\u00e3o dos princ\u00edpios ativos, proporcionando ao medicamento uma \n\nlibera\u00e7\u00e3o modificada ou s\u00edtio-espec\u00edfica, com in\u00fameras vantagens terap\u00eauticas \n\ne econ\u00f4micas (SILVA et al., 2003). As vantagens terap\u00eauticas s\u00e3o: libera\u00e7\u00e3o \n\nprecisa de baixas doses de f\u00e1rmacos potentes, redu\u00e7\u00e3o da concentra\u00e7\u00e3o do \n\nf\u00e1rmaco em outros locais que n\u00e3o os \u00f3rg\u00e3os ou tecidos alvo e prote\u00e7\u00e3o dos \n\ncompostos l\u00e1beis, antes e depois da administra\u00e7\u00e3o, at\u00e9 exercerem a sua a\u00e7\u00e3o \n\nfarmacol\u00f3gica (SILVA et al., 2003). As micropart\u00edculas tamb\u00e9m promovem um \n\nconsider\u00e1vel aumento da taxa de dissolu\u00e7\u00e3o de f\u00e1rmacos com baixa \n\nsolubilidade como \u00e9 o caso da indometacina, antiinflamat\u00f3rio praticamente \n\ninsol\u00favel em \u00e1gua (FINI; CAVALLARI; OSPITALI, 2008).  \n\n As tecnologias mais utilizadas para se obter micropart\u00edculas s\u00e3o a \n\ncoacerva\u00e7\u00e3o, evapora\u00e7\u00e3o de solvente, leito fluidizado, extrus\u00e3o, spray drying e \n\nspray congealing. Recentemente a t\u00e9cnica de spray congealing, tamb\u00e9m \n\nconhecida como spray chilling ou spray cooling, est\u00e1 ganhando consider\u00e1vel \n\naten\u00e7\u00e3o, especialmente do ponto de vista da seguran\u00e7a e rapidez (ALBERTINI \n\net al., 2008). O spray congealing tamb\u00e9m apresenta a vantagem de produzir \n\nmicropart\u00edculas com forma esf\u00e9rica, tamanhos na escala microm\u00e9trica, e o \n\nf\u00e1rmaco \u00e9 distribu\u00eddo uniformemente dentro de todo o volume da part\u00edcula (ILIC \n\net al., 2009). Al\u00e9m do mais, nas \u00faltimas duas d\u00e9cadas, o spray congealing tem \n\natra\u00eddo aten\u00e7\u00e3o, pois n\u00e3o requer o uso de solventes aquosos ou org\u00e2nicos, \n\nsendo considerada uma t\u00e9cnica ambientalmente correta, e quando comparada \n\na outras t\u00e9cnicas como o spray drying consome menos energia e tempo \n\n(PASSERINI et al., 2009). Outra vantagem \u00e9 a facilidade de produ\u00e7\u00e3o em larga \n\nescala devido ao fato de poder ser operada continuamente eliminando etapas \n\nde produ\u00e7\u00e3o (EMAS; NYQVIST, 2000). Nesta t\u00e9cnica as micropart\u00edculas s\u00e3o \n\nobtidas a partir de uma dispers\u00e3o (mistura do f\u00e1rmaco e carreador fundido, \n\n\n\n \n\n  \n\n11\n\ngeralmente 10\u00baC acima do ponto de fus\u00e3o do carreador) que \u00e9 nebulizada \n\natrav\u00e9s de um bico atomizador produzindo got\u00edculas que posteriormente \n\nentram em contato com uma corrente de ar frio causando a solidifica\u00e7\u00e3o do \n\nve\u00edculo e formando as micropart\u00edculas (PASSERINI et al., 2002).  \n\n Uma aplica\u00e7\u00e3o que vem sendo estudada \u00e9 o uso do spray congealing na \n\nprepara\u00e7\u00e3o de micropart\u00edculas lip\u00eddicas carregadas com prote\u00ednas e pept\u00eddeos. \n\nO desenvolvimento de sistemas de libera\u00e7\u00e3o contendo estas subst\u00e2ncias \u00e9 \n\numa tarefa desafiadora, j\u00e1 que, \u00e9 necess\u00e1rio manter a prote\u00edna \u00edntegra e \n\nbioativa durante o processo de encapsula\u00e7\u00e3o. A t\u00e9cnica tamb\u00e9m vem \n\ndemonstrando \u00f3timos resultados em estudos de perfis de dissolu\u00e7\u00e3o in vitro, \n\nvisto que o desenvolvimento de formula\u00e7\u00f5es visando o melhoramento da taxa \n\nde libera\u00e7\u00e3o de f\u00e1rmacos pouco sol\u00faveis representa um importante desafio na \n\n\u00e1rea farmac\u00eautica (FINI, CAVALLARI; OSPITALI, 2008). O spray congealing foi \n\nempregado com sucesso na prepara\u00e7\u00e3o de micropart\u00edculas carregadas com \n\nf\u00e1rmacos pouco sol\u00faveis como a carbamazepina (PASSERINI et al, 2002), \n\nindometacina (FINI et al., 2002), o praziquantel (PASSERINI et al., 2006), \n\ndiclofenaco (CAVALLARI et al. , 2005), glimepirida (ILIC et al., 2009), entre \n\noutros. \n\n Assim o spray congealing surge como uma tecnologia promissora na \n\nmanufatura de micropart\u00edculas de f\u00e1rmacos pouco sol\u00faveis, melhorando \n\nconsideravelmente a taxa de dissolu\u00e7\u00e3o desses f\u00e1rmacos. \n\n Este trabalho visou \u00e0 prepara\u00e7\u00e3o de dispers\u00f5es s\u00f3lidas de \n\ncarbamazepina (CBZ) com os carreadores polioxilglicer\u00eddeo (Gelucire\u00ae 50/13), \n\ne polietilenoglic\u00f3is (PEG 4000 e PEG 6000) para estudos de melhoramento da \n\nsolubilidade da CBZ. A dispers\u00e3o de CBZ com Gelucire\u00ae 50/13 liquefeito foi \n\nutilizada para obter micropart\u00edculas usando a t\u00e9cnica de spray congealing. \n\nAtrav\u00e9s de um planejamento experimental do tipo Box-Behnken, foi poss\u00edvel \n\nestudar a influ\u00eancia de alguns fatores deste processo sobre par\u00e2metros como \n\ntamanho de part\u00edcula, rendimento do processo (ILIAC et al, 2009), efici\u00eancia de \n\nencapsula\u00e7\u00e3o (ALBERTINI, et al, 2008), escoabilidade (ARA\u00daJO, TEXEIRA, \n\nFREITAS, 2010), entre outros (AULTON, 2005). As micropart\u00edculas foram \n\ncaracterizadas com o uso de t\u00e9cnicas espec\u00edficas para avalia\u00e7\u00e3o de suas \n\ncaracter\u00edsticas f\u00edsico-qu\u00edmicas e farmacot\u00e9cnicas (DHIRENDRA, 2009). \n\n \n\n\n\n \n\n  \n\n12\n\n6. CONCLUS\u00d5ES \n\nNa primeira etapa deste trabalho pode-se concluir que o preparo e \n\nobten\u00e7\u00e3o da dispers\u00e3o s\u00f3lida de CBZ com Gelucire\u00ae 50/13 na propor\u00e7\u00e3o de 1:9 \n\nmelhorou de maneira significativa a solubilidade da carbamazepina quando \n\ncomparada ao f\u00e1rmaco puro. \n\nNos estudos f\u00edsico-qu\u00edmicos a CBZ e o Gelucire 50/13 mostraram ser \n\nest\u00e1veis a temperaturas abaixo de 200 \u00baC. O preparo da dispers\u00e3o s\u00f3lida (1:9) \n\nmostrou que n\u00e3o houve intera\u00e7\u00f5es entre f\u00e1rmaco e carreador. Entretanto, a \n\nfus\u00e3o e tempo de aquecimento conduziu a forma\u00e7\u00e3o da foma I da CBZ, \n\nevidenciada pelos resultados de difra\u00e7\u00e3o de raio-X e HSM. \n\nNa segunda etapa de preparo e obten\u00e7\u00e3o das micropart\u00edculas a t\u00e9cnica \n\nde spray congealing mostrou-se muito r\u00e1pida e eficiente. Todos os \n\nexperimentos apresentaram bons rendimentos (54 a 80 %), baixo teor de \n\numidade (<2 %), baixa atividade de \u00e1gua (<0,550) e bom conte\u00fado de f\u00e1rmaco. \n\nCom a utiliza\u00e7\u00e3o do planejamento Box-Benhken p\u00f4de-se estudar as \n\nvari\u00e1veis do processo, evidenciando a influ\u00eancia dessas vari\u00e1veis nos \n\nresultados obtidos. As vari\u00e1veis influenciaram no processo de maneira \n\nsignificante nos resultados de rendimento e teor de umidade.  \n\nNa avalia\u00e7\u00e3o da escoabilidade dos microparticulados os experimentos \n\nmostraram fluxo de bom a moderado utilizando t\u00e9cnicas simples e r\u00e1pidas para \n\nsua caracteriza\u00e7\u00e3o. \n\nOs estudos do tamanho e morfologia mostraram que as part\u00edculas \n\npossuem um tamanho entre 53,09 a 78,75 \u00b5m, com forma esf\u00e9rica, superf\u00edcie \n\nlisa com algumas irregularidades e aparentemente n\u00e3o porosa.  \n\nPara todas as micropart\u00edculas a solubilidade da CBZ apresentou um \n\naumento semelhante \u00e0 dispers\u00e3o s\u00f3lida, sendo aproximadamente 2,70 vezes \n\nmaior do que a da CBZ pura.  \n\nAs caracter\u00edsticas do estado s\u00f3lido das micropart\u00edculas foram \n\nsemelhantes \u00e0 da dispers\u00e3o s\u00f3lida (1:9), ou seja, com aus\u00eancia de intera\u00e7\u00f5es \n\nqu\u00edmicas e com a forma\u00e7\u00e3o do polimorfo I. \n\nAs micropart\u00edculas estudadas conduziram a um aumento na taxa de \n\ndissolu\u00e7\u00e3o in vitro da CBZ quando comparada a sua respectiva dispers\u00e3o \n\ns\u00f3lida e a CBZ pura. Portanto, o spray congealing, \u00e9 um m\u00e9todo promissor \n\n\n\n \n\n  \n\n13\n\npara ser empregado na fabrica\u00e7\u00e3o de micropart\u00edculas de f\u00e1rmacos pouco \n\nsol\u00faveis, merecendo ser estudado aprofundadamente. \n\n \n \nREFER\u00caNCIAS \n\n \n\nAFTABROUCHAD, C.; DOELKER, E. Preparation methods for biodegradable \n\nmicroparticles loaded with water-soluble drugs. STP Pharma Sciences, v. 2, p. \n\n365- 380, 1992. \n\n \n\nAMBROGI, V.; PERIOLI, L.; MARMOTTINI, F.; ACCORSI, O.; PAGANO, C.; \n\nRICCI, M.; ROSSI, C. Role of mesoporous silicates on carbamazepine \n\ndissolution rate enhancement. Microporous and Mesoporous Materials, v. \n\n113, p. 445 \u2013 452, 2008.   \n\n \n\nAMERI, M.; MAA, Y-F. Spray drying of biopharmaceuticals: stability and process \n\nconsiderations, Drying Technology, v. 24, p. 763-768, 2003. \n\n \n\nAMIDON; G. L.; LENNERNAS; H.; SHAH; V. P.; CRISON; JR. A theoretical \n\nbasis for a biopharmaceutics drug classification: The correlation of in vitro drug \n\nproduct dissolution and in vivo bioavailability. Pharmaceutical Research, v. 12, \n\np. 413-420, 1995. \n\n \n\nANSEL, H. C.; POPOVICH, N. G.; ALLEN JR., L. V. Farmacot\u00e9cnica: formas \n\nfarmac\u00eauticas e sistemas de libera\u00e7\u00f5es de f\u00e1rmacos. 6 ed. S\u00e3o Paulo. \n\nEditora premier, 2000, 508 p. \n\n \n\nALBERTINI, B.; PASSERINI, N.; PATTARINO, F.; RODRIGUEZ, L. New spray \n\ncongealing atomizer for the microencapsulation of highly concentrated solid and \n\nliquid substances. European Journal of Pharmaceutics and \n\nBiopharmaceutics, v. 69, p. 348-357, 2008. \n\n \n\nARA\u00daJO, R. R. TEIXEIRA C. C. C., FREITAS L. A. P. The preparation of ternary \n\nsolid dispersions of an herbal drug via spray drying of liquid feed, Drying \n\n\n\n \n\n  \n\n14\n\nTechnology, v. 28 p. 412-421, 2010. \n\n \n\nAULTON, M. E. Delineamento de formas farmac\u00eauticas. 2 ed. Porto Alegre: \n\nAtmed, 2005. 34~36p.  \n\nBABU, V. R.; AREEFULLA, S. H.; MALLIKARJUN, V. Solubility and dissolution \n\nenhancement: An overview. Journal of Pharmacy Research, v. 3p. 141-145, \n\n2010. \n\nBORINI, G.B.; ANDRADE, T. C.; FREITAS, L.A.P. Hot melt granulation of \n\ncoarse pharmaceutical powders in a spouted bed. Powder Technology, v. 189, \n\np. 520-527, 2009.. \n\n \n\nBORINI, G.B.; FREITAS, L.A.P. Study on the Spray Congealing of a \n\nPharmaceutical Wax. Proceedings of 15th International Drying Symposium, \n\nEd. A.S. Mujumdar and I. Farkas, Budapest, Hungary, p. 1169-1173, 2006.. \n\nBOX, M. J.; HUNTER, W. G.; HUNTER, J. S. Statistics for Experimenters: An \n\nIntroduction to Design. New York: John Wiley &amp; Sons, 1978. \n\nBRASIL, Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA) Resolu\u00e7\u00e3o, RE n\u00ba \n\n901, de 29 de maio de 2003, publicada no di\u00e1rio oficial da uni\u00e3o, 02 de junho \n\nde 2003. Guia para ensaios de dissolu\u00e7\u00e3o para formas farmac\u00eauticas s\u00f3lidas \n\norais de libera\u00e7\u00e3o imediata. Bras\u00edlia, 2003. \n\nBRASIL. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria \u2013 ANVISA. Guia para \n\nvalida\u00e7\u00e3o de m\u00e9todos anal\u00edticos e bioanal\u00edticos. RE n\u00b0 899, de 29 de maio de \n\n2003, Bras\u00edlia, 2003.  \n\nBREITENBACH, J. Melt extrusion: from process to drug delivery technology. \n\nEuropean Journal of Pharmaceutics and Biopharmaceutics, v.54, p. 107-\n\n117, 2002. \n\n \n\nBREITENBACH, J.; LEWIS, J. Two concepts, one technology: controlled \n\n\n\n \n\n  \n\n15\n\nrelease and solid dispersion with meltrex. In Modified-Release Drug delivery \n\ntechnology, p. 125-134, 2005. \n\n \n\nCEBALLOS, A.; CIRRI, M.; MAESTRELLI, F.; CORTI, G.; MURA, P. Influence \n\nof formulation and process variables on in vitro release of theophylline from \n\ndirectly-compressed Eudragit matrix tablets. Il Farmaco, v. 60, p. 913-918, \n\n2005. \n\n \n\nCHAMBI, H. N. M.; ALVIM, I.D.; BARRERA-ARELLANO, D.; GROSSO, C. R. F. \n\nSolid lipid microparticles containing water-soluble compounds of different \n\nmolecular mass: production, characterization and release profiles. Food \n\nResearch International, v. 41, p. 229-236, 2008. \n\n \n\nCHARSLEY, E. L. Complementary Thermal Analysis Methods in Thermal \n\nAnalysis Techniques and Applications, The Royal Society of Chemistry, \n\nCambridge, p. 68-74, 1992. \n\n \n\nCHAVDA, H. V.; PATEL, C. N.; ANAND, I. S.Biopharmaceutics classification \n\nsystem. Systematic Reviews in Pharmacy, v.1, p. 62-69, 2010. \n\n \n\nCHOPRA, S., MOTWANI, S.,K., IQBAL, Z., TALEGAONKAR, S., AHMAD, F., J., \n\nKHAR, R., K. Optimisation of polyherbal gels for vaginal drug delivery by Box-\n\nBenhken statistical design. European Journal of Pharmaceutics and \n\nBiopharmaceutics. .67, p. 120-131, 2007. \n\n \n\nCRAIG, D.Q.M. The mechanisms of drug release from solid dispersions in \n\nwater-soluble polymers. International Journal of Pharmaceutics, v. 231, p. \n\n131-144, 2002. \n\n \n\nDAMIAN, F.; BLATON, N.; NAESENS, L.; BALZARINI, J.; KINGET, R.; \n\nAUGUSTIJNS, P.; MOOTER DEN, G. V. Physicochemical characterization of \n\nsolid dispersion of the antiviral agent UC-781 with polyethylene glycol 6000 and \n\nGelucire 44/14. European Journal of Pharmaceutical Sciences, v. 10, p. 311-\n\n322, 2000.  \n\n\n\n \n\n  \n\n16\n\n \n\nDESAI, J.; ALEXANDER, K.; RIGA, A. Characterization of polymeric dispersions \n\nof dimenhydrinate in ethyl cellulose for controlled release. International \n\nJournal of Pharmaceutics v. 308, p. 115\u2013123, 2006. \n\n \n\nDHIRENDRA, K.; LEWIS, S.; UDUPA, N.; ATIN, K.; Solid dispersions: a review, \n\nPakistan Journal of Pharmaceutical Sciences, v. 22 (2009); pp. 234-246. \n\n \n\nDOSHI, D. H.; RAVIS, W. R.; BETAGERI, G. V. Carbamazepine and \n\npolyethylene  glycol solid dispersions: Preparation, in vitro dissolution, and \n\ncharacterization. Drug Development and Industrial Pharmacy, v. 23, p. 1167-\n\n1176, 1997.   \n\n \n\nDRESSMAN, J. R.; AMIDON, G. L.; REPPAS, C.; SHAH, V. Dissolution testing \n\nas a prognostic tool for oral drug absorption: immediate release dosage forms. \n\nPharmaceutical Research, v. 15, p. 11-22, 1998. \n\n \n\nDRESSMAN, J. BJ.; HEMPESTALL, J.; REPPAS, C. The BCS: Where do we go \n\nfrom Here? Pharmaceutical Technology, p. 68-76, 2001.  \n\n \n\nDORMANB, R. G. The atomization of liquid in a flat spray, British Journal of \n\nApplied Physics v. 3,p. 189-192, 1952. \n\n \n\nEMAS, M.; NYQVIST, H. Methods of studying aging and stabilization of spray-\n\ncongealing solid dispersions with carnauba wax. l. Microcalorimetric \n\ninvestigation. International Journal of Pharmaceutics, v, 197, p. 117-127, \n\n2000. \n\n \n\nFERREIRA, S. L. C.; BRUNS, R. E.; FERREIRA, H. S.; MATOS, G. D.; DAVID, \n\nJ. M.; BRAND\u00c3O, G. C.; SILVA, E. G. P.; PORTUGAL, L. A.; REIS, P. S.; \n\nSOUZA, A. S.; SANTOS, W. N. L. Box-Behnken design: Na alternative for the \n\noptimization of analytical methods.  Analytica Chimica Acta. v.597, p. 179-186, \n\n2007. \n\n \n\n\n\n \n\n  \n\n17\n\nFINI, A.; MOYANO, J. R.; PERZ-MARTINEZ, J. I.; RABASCO, A. M. Diclofenac \n\nsalts, II. Solid dispersions in PEG 6000and Gelucire 50/13. European Journal \n\nof Pharmaceutics and Biopharmaceutics, v. 60, p. 99-11, 2005. \n\n \n\nFINI, A.; CAVALLARI, C.; OSPITALI, F. Rhaman and thermal analisis of \nindomethacin/PVP solid dispersion enteric microparticles. European Journal of \nPharmaceutics and Biopharmaceutics, v. 70, p. 409-420, 2008.  \n \n\nFreitas, L. A. P., Andrade, T. C., Teixeira, C. C. C., Tacon, L. A., Tsukada, M. \n\nInnovative applications of spray drying. Chapter No 1 of Advances in \n\nChemical Engineering/ ed. Maria Jose San Jose, Transworld Res. Network, \n\nKerala, India, 2010 1-12p. \n\n \n\nGHOSH SK. Functional coatings and microencapsulation: A general \n\nperspective. Ch 1. Wiley-VCH, Verlag GmbH &amp; Co. KGoaA, Weinheim. Green \n\nBK. 1960. US Patent Re 24:899. \n\n \n\nGIBBS, B. F.; KERMASHA, S.; ALLI, I.; MULLIGAN, C. N. Encapsulation in the \n\nfood industry: a review. International Journal of Food Sciences and \n\nNutration. v. 50, p. 213-224, 1999.  \n\n \n\nGUO, C.; STINE , K., J.; KAUFFMAN, J., F.; DUOB, W., H. Assessment of the \n\ninfluence factors on in vitro testing of nasal sprays using Box-Benhken \n\nexperimental desing. European Journal of pharmaceutical sciences, v. 35, p. \n\n417-426, 2008. \n\n \n\nHANDANI, J.; M\u00d6ES, A.; AMIGHI, K. Physical and thermal characterisation of \n\nPrecirol\u00ae and Compritol\u00ae as lipophilic glycerides used for the preparation of \n\ncontrolled-release matrix pellets. International of Pharmaceutics, v. 260, p.47-\n\n57, 2003. \n\nHITE, M.; TURNER, S.; FEDERICI, C. Part 1: Oral delivery of poorly soluble \n\ndrugs, PMPS Summer, v. 1, p. 38-40, 2003. \n\n \n\nH\u00d6TER, D.; DRESSMAN, J. B.; Influence physicochemical properties on \n\ndissolution of drugs in the gastrointestinal. Advanced drug delivery reviews, v \n\n\n\n \n\n  \n\n18\n\n46,p. 75-87, 2001. \n\n \n\nHUANGA, J.; WIGENT, R. J.; BENTZLEY, C. M.; SCHWARTZ, J. B. Nifedipine \n\nsolid dispersion in microparticles of ammonio methacrylate copolymer and \n\nethylcellulose binary blend for controlled drug delivery. Effect of drug loading on \n\nrelease kinetics. International Journal of Pharmaceutics, v. 319, p. 44-54, \n\n2006. \n\n \n\nILIC, I.; DREU, R.; BURJAK, M.; HOMAR, M.; KERC, J.; SRCIC. S. \n\nMicroparticle size control and glimepiride microencapsulation using spray \n\ncongealing technology. International Journal Pharmaceutics, v. 381, p. 176-\n\n183, 2009. \n\n \n\nJACHOWICZ, R. Dissolution rates of partially water-soluble drugs from solid \n\ndispersion systems. I. Predinizolone. International Journal of Pharmaceutics, \n\nv, 35, p. 1-5, 1987. \n\n \n\nJAFARI, S. M.; ASSADPOOR, E.; HE, Y.; BHANDARI, B. Encapsulation \n\nefficiency of food flavours and oils during spray drying. Drying technology, v. \n\n26, p. 816-835, 2008. \n\n \n\nJEFERRY, G. H.; BASSET, J.; MENDHAM, J.; DENNEY, R. C. Vogel: an\u00e1lise \n\nqu\u00edmica quantitative. 5 ed. LTC Editora, Rio de janeiro, 1992. \n\n \n\nJOHARI, G. P.; KIM, S.; SHANKER, R. M. Dielectric studies of molecular \n\nmotions in amorphous solid and ultraviscous acetaminophen. Journal of \n\npharmaceutical sciences, v. 94, p. 2207-2223, 2005. \n\n \n\nJYOTHI, N. V. N.; PRASANNA, P. M.; SAKARKAR, S. N.; PRABHA, K. S.; \n\nRAMAIAH, P. S.; SRAWAN, G. Y. Microencapsulation techniques, factor \n\ninfluencing encapsulation efficiency. Journal of microencapsulation, v. 27, p. \n\n187-197, 2010. \n\n \n\nIONASHIRO, M.; GIOLITO, L. Nomenclatura, padr\u00f5es e apresenta\u00e7\u00e3o dos \n\n\n\n \n\n  \n\n19\n\nresultados em an\u00e1lise t\u00e9rmica. Cer\u00e2mica, S\u00e3o Paulo, v.26, n.121, 1980, p.17-\n\n24,  \n\n \n\nKANENIWA, N., YAMAGUCHI, T., WATARI, N., OTSUKA, M. Hygroscopicity of \n\ncarbamazepine crystalline powders. Yakugaku Zasshi, v. 104, p. 184-190, \n\n1984.. \n\nKARATAS, A.; Y\u00dcKSEL, N.; BAYKARA, T. Improved solubility nand dissolution \n\nrate of pyroxicam using gelucire 44/14 and labrasol. Il Farmaco, v. 60, p. 777-\n\n782, 2005. \n\n \n\n KARAVAS, E.; GEORGARAKIS, E.; BIKIARIS, D. Application of PVP/HPMC \n\nmiscible blends with enhanced mucoadhesive properties for adjusting drug \n\nrelease in predictable pulsatile chronotherapeutics. European Journal of \n\nPharmaceutics and Biopharmaceutics, v. 64, p. 115-126, 2006. \n\n \n\nKAS, H. S.; ONER, L. Handbook of Pharmaceutical controlled release \n\ntechnology. New York: Marcel-Dekker, 2000. p. 301-328. \n\n \n\nKILLEN, M. J. The process of spray drying and spray congealing. \n\nPharmaceutical Engineering, v. 13, p. 56-64, 1993. \n\n \n\nKOBAYASHI, Y.; ITO, S.; ITAI, S.; YAMAMOTO, K. Physicochemical properties \n\nbioavailibity of carbamazepine polymorphs and dehydrate. International of \n\nPharmaceutics, v. 193, p. 137-146, 2000. \n\n \n\nLEUNER, C.; DRESSMAN, J. Improving drug solubility for oral delivery using \n\nsolid dispersions. European Journal of Pharmaceutics and \n\nBiopharmaceutics, v. 50, p. 47-60, 2000.  \n\n \n\nLINGAM, M.; VENKATESWARLU, V. Enhancement of solubility and dissolution \n\nrate of poorly water soluble drug using cosolvency and solid dispersion \n\ntechniques. International Journal of Pharmaceutical Sciences and \n\nNanotechnology, v. 1, p. 349-356, 2009. \n\n \n\n\n\n \n\n  \n\n20\n\nLLOYD, G. R.; CRAIG, D. Q. M.; SMITH, A. A calorimetric investigation into \n\nthe interaction between paracetamol and polyethlene glycol 4000 in physical \n\nmixes and solid dispersions. European Journal of Pharmaceutics and \n\nBiopharmaceutics v.48, p. 59-65, 1999. \n\n \n\nMACHISTE, E. O.; GIUNCHEDI, P.; SETTI, M.; CONTE, U. Characterization of \n\ncarbamazepine in systems containing a dissolution rate enhancer. \n\nInternational journal of pharmaceutics, v. 126, p. 65-72, 1995.  \n\n \n\nMCCARRON, P. A.; DONNELLY, R. F.; AL-KASSAS R. Comparison of a novel \n\nspray congealing procedure with emulsion-based methods for the micro-\n\nencapsulation of water-soluble drugs in low melting point triglycerides. Journal \n\nof Microencapsulation, v. 25, p. 365-378, 2008. \n\n \n\nMASCHKE, A.; BECKER, C.; EYRICH, D.; KIERMAIER, J.; BLUNK, T.; \n\nGOPFERICH, A. Desenvolviment of a spray congealing process for the \n\npreparation of insulin-loaded lipid microparticles and characterization thereof.  \n\nEuropean Journal of Pharmaceutics and Biopharmaceutics, v. 65, p. 175-\n\n187, 2007. \n\n \n\nMAYOCLINIC.COM. Tools for healthier lives. Drugs &amp; Supplements. Dispon\u00edvel \n\nem: http://www.mayoclinic.com/health/drug-information/DR600349. Acesso em: \n\n27 de novembro de 2008.  \n\n \n\nNAIR, R.; GONEN, S.; STEPHEN, W. H. Influence of polyethylene glycol and \n\npovidone on the polymorphic transformation and solubility of carbamazepine. \n\nInternational of Pharmaceutics, v. 240, p. 11-22, 2002. \n\n \n\nOKONOGI, S.; OGUCHI, T.; YONEMOCHI, E.; PUTTIPIPATKHACHORN, S.; \n\nYAMAMOTO, K. Improved dissolution of ofloxacin via solid dispersion. \n\nInternational Journal of Pharmaceutics, v, 156, p. 175-180, 1997. \n\n \n\nOTSUKA, M.; OHFUSA, T.; MATSUDA, Y. Effect of bindeof polymorphic \n\ntransformation kinetics of carbamazepine in aqueous solution. Colloids \n\n\n\n \n\n  \n\n21\n\nsurfaces B: Biointerferencis, v. 17, p. 145-152, 2000. \n\n  \n\nPAGLIARUSSI, R. S., BASTOS; J. K.; FREITAS, L. A. P. Fluid bed drying og \n\nGuarana (Paullinia cupana HBK ) extract: effect of process factors on caffeine \n\ncontent. AAPS PharmaSciTech. 7 (2), article - 54, 2006. \n\n \n\nPARIKH, R.H.; PARIKH, J. R.; DUBEY, R. R.; SONY, H. N.; KAPADIA, K. N. \n\nPoly (D,L-lactide-co-glycolide) microspheres containing 5-fluorouracil: \n\noptimization of process parameters. AAPS PharmaSciTech. v 4, n.2, E. 13, \n\n2003.   \n\n \n\nPARROT, E., L. Pharmaceutical technology: fundamental pharmaceutics. \n\nMinneapolis: Burgess Publishing Company; 1970. 3-11p. \n\n \n\nPASSERINI, P.; PERISSUTTI, B.; MONEGHINI, M.; VOINOVICH, D.; \n\nALBERTINI, B.; CAVALLARI, C.; RODRIGUEZ, L. Characterization of \n\ncarmazepine-gelucire 50/13 microparticles prepared by a spray-congealing \n\nprocess using ultrasounds. Journal of Pharmaceutical Sciences, v. 91, p. \n\n699-707, 2002. \n\n \n\nPASSERINI, N.; PERISSUTI, B.; ALBERTINI, B.; VOINOVICH, D.; \n\nMONEGHINI, M.; RODRIGUEZ, L. Controlled release of verapamil \n\nhydrochloride from waxy microparticles prepared by spray congealing. Journal \n\nof Controlled release, v. 88, p. 263-275, 2003. \n\n \n\nPASSERINI, N.; ALBERTINI, B.; PERISSUTI, B.; RODRIGUEZ, L. Evaluation of \n\nmelt granulation and ultrasonic spray congealing as techniques to enhance the \n\ndissolution of praziquantel. International Journal of Pharmaceutics, v. 318, p. \n\n92-102, 2006. \n\n \n\nPOKHARKAR, V. B.; MANDPE, L. P.; PADAMWAR, M. N.; AMBIKE, A. A.; \n\nMAHADIK, K. R.; PARADKAR, A. Development, characterization and \n\nstabilization of amorphous form of a low Tg drug. Powder Technology, v. 167 \n\np. 20-25, 2006. \n\n\n\n \n\n  \n\n22\n\n \n\nPORTERO, A.; REMUNANLOPEZ, C.; VILAJATO, J. L. Effect of chitosan and \n\nchitosan glutamato enhancing the dissolution properties of the poorly water \n\nsoluble drugs nifedipine. International Journal of Pharmaceutics, v. 175, p. \n\n75-84, 1998. \n\n \n\n \n\nPOUT, C. W. Formulation of poorly water-soluble drugs for oral administration: \n\nphysicochemical and physiological issues and the lipid formulation classification \n\nsystem. European Journal of pharmaceutical sciences, v. 29, p. 278-287, \n\n2006. \n\n \n\nPRABHU, S.; ORTEGA, M.; MA, C. Novel lipid-based formulations enhancing \n\nthe in vitro dissolution and permeability characteristics of a poorly water-soluble \n\nmodel drug, piroxicam. International Journal of Pharmaceutics, v. 301, p. \n\n209-216, 2005.  \n\n \n\nRATES, A. L. R.;OLIVEIRA, W. P. Spray drying conditions and encapsulation \n\ncomposition effects on formation and properties of sodium diclofenac \n\nmicroparticles. Powder technology, v. 171, p. 7-14, 2007. \n\n \n\nRODRIGUES, M. I.; LEMMA, A. F. Planejamentos de experimentos e \n\notimiza\u00e7\u00e3o de processos. Campinas, SP: Casa do Esp\u00edrito Amigo F\u00e9 e Amor, \n\n2009. \n\n  \n\nRUSTICHELLI, C.; GAMBERINI, G.; FERIOLI, V.; GAMBERINI, M. C.; \n\nFICARRA, R.; TOMMASINI, S. Solid-state study of polymorphic drugs: \n\ncarbamazepine. Journal of Pharmaceutical and Biomedical Analysis, v. 23, \n\np. 41-54, 2000. \n\n \n\nSAVOLAINEN, M.; KHOO, C.; GLAD, H.; DAHLQVIST, C.; JUPPO, A.M. \n\nEvaluation of controlled-release polar lipid microparticles. International \n\nJournal of Pharmaceutics, v. 244, p. 151-161, 2002. \n\n \n\n\n\n \n\n  \n\n23\n\nSEO, A.; HOLM, P.; KRISTENSEN, H. G.; SCHAEFER, T. The preparation of \n\nagglomerates containing solid dispersions of diazepam by melt agglomeration \n\nin a high shear mixer. International of Pharmaceutics, v. 259, p. 161-171, \n\n2003. \n\n \n\nSEKIGUCHI, K.; OBI, N. Studies on absorption of eutectic mixtures. II. A \n\nabsorption of fused conglomerates of chloramphenicol and urea in rabbits. \n\nChemical Pharmaceutical Bull, v.12, p. 134-144, 1964. \n\n \n\nSEKIGUCHI, K.; OBI, N. Studies on absorption of eutectic mixtures. II. A \n\ncomparison of the behavior of eutectic mixturesof sulphathiazole and that of \n\nordinary sulphathiazole in man. Chemical Pharmaceutical Bull, v.9, p. 866-\n\n872, 1961. \n\n \n\nSEO, A.; HOLM, P.; KRISTENSEN, H. G.; SCHAEFER, T. The preparation of \n\nagglomerates containing solid dispersions of diazepam by melt agglomeration \n\nin a high shear mixer. International Journal of Pharmaceutics, v. 259, p. \n\n161\u2013171, 2003. \n\n \n\nSETHIA, S.; SQUILLANTE, E. Physicochemical characterization of solid \n\ndispersions of carbamazepine formulated by supercritical carbon dioxide and \n\nconventional solvent evaporation method. Journal of Pharmaceutical \n\nSciences, v. 91, n. 9, 2002. \n\n \n\nSERAJUDDIN, A.T.M. Solid Dispersion of poorly water-soluble: early promises, \n\nsubsequent problems, and recents breakthroughs. Journal of Pharmaceutical \n\nsciences, v. 88 (10): 1058-1066, 1999. \n\n \n\nSHARMA, D.; SONI, M.; KUMAR, S.; GUPTA, G. D. Solubility enhancement \u2013 \n\nEminent role in poorly soluble drugs. Research Journal Pharmacy and \n\nTechnology,  v. 2, p. 220-224, 2009. \n\n   \n\nSILVA, C.; RIBEIRO, A.; FERREIRA, D.; VEIGA, F. Administra\u00e7\u00e3o oral de \n\npept\u00eddeos e prote\u00ednas: ll. aplica\u00e7\u00e3o de m\u00e9todos de microencapsula\u00e7\u00e3o. Revista \n\n\n\n \n\n  \n\n24\n\nBrasileira de Ci\u00eancias Farmac\u00eauticas, v. 39, p. 01-20, 2003. \n\n \n\nSOUZA, J.; FREITAS, Z. M. F.; STORPIRTIS, S. Modelos in vitro  para a \n\ndetermina\u00e7\u00e3o da absor\u00e7\u00e3o de f\u00e1rmacos e previs\u00e3o da rela\u00e7\u00e3o \n\ndissolu\u00e7\u00e3o/absor\u00e7\u00e3o. Revista Brasileira de Ci\u00eancias Farmac\u00eauticas, S\u00e3o \n\nPaulo, v. 43, n. 4, p. 515-527, 2007. \n\n \n\nSTORPIRTIS, S.; GON\u00c7ALVES, J. E.; CHIANN, C.;;; GAI, M. N. Ci\u00eancias \n\nFarmac\u00eauticas Biofarmacot\u00e9cnica. Rio de Janeiro, Guanabara Koogan, 2009, \n\np. 25-28.  \n\n \n\nSUTANANTA, W.; CRAIG, D. Q. M.; NEWTON, J. M. The effects of ageing on \n\nthe thermal behavior and mechanical properties of pharmaceutical glycerides. \n\nInternational of Pharmaceutics, v.111, p. 51-62, 1994. \n\n \n\nSWARBRIK, J. Encyclopedia of pharmaceutical technology. New York London: \n\nInforma, 2007. p. 766-777. \n\n \n\nUNITED STATES PHARMACOPEIA USP 30 \u2013 NF25. Rockville:The United \n\nStates Pharmacopeial Convection, 2007. \n\n \n\nVAN DROOGE, D. J.; HINRICHS, W.L.J.; VISSER, M.R. FRIJLINK, H.W. \n\nCharacterization of the molecular distribution of drugs in glassy solid \n\ndispersions at the nano-meter scale, using differential scanning calorimetry and \n\ngravimetric water vapour sorption techniques. International Journal of \n\nPharmaceutics, v. 310 p. 220\u2013229, 2006. \n\n \n\nVASCONCELOS, T.; SARMENTO, B.; COSTA, P. Solid dispersions as strategy \n\nto improve oral bioavailability of poor water soluble drugs. Drug Discovery \n\nToday, v.12, p. 1068-1075, 2007. \n\n \n\nVERRECK,G.; DECORTE, A.; HEYMANS, K.; ADRIAENSEN, J.; GLEEREN, \n\nD.; JACOBS, A.;LIU, D.; TOMASKO, D.; ARIEN, A.; PEETERS, J.; ROMBAUT, \n\nP.; VAN DEN MOOTER, D.; BREWSTER, M. E. The effect of pressurized \n\n\n\n \n\n  \n\n25\n\ncarbon dioxide as a temporary plasticizer and foaming agent on the hot stage \n\nextrusion process and extrudate properties of solid dispersions of itraconazole \n\nwith PVP-VA 64. European Journal of Pharmaceutical Sciences, v. 26, p. \n\n349-358, 2005. \n\n \n\nVERRECK, G.; DECORTE, A.; HEYMANS, K.; ADRIAENSEN, J.; LIU, D.; \n\nTOMASKO, D. L.; ARIEN, A.; PEETERS, J.; ROMBAUT, P.; VAN DEN \n\nMOOTER, G.; BREWSTER, M. E. The effect of supercritical CO2 as a \n\nreversible plasticizer and foaming agent on the hot stage extrusion of \n\nitraconazole with EC 20 cps. The Journal of Supercritical Fluids, v. 40, p. \n\n153\u2013162, 2007. \n\n \n\nVILHELMSEN, T.; ELIASEN, H.; SCHAEFER, T. Effect of a melt agglomeration \n\nprocess on agglomerates containing solid dispersions. International Journal of \n\nPharmaceutics v. 303, p. 132-142, 2005. \n\n \n\nVITEZ,I. M.; NEWMAN, A. W.; DAVIDOVICH, M.; KIESNOWSKI, C. The \n\nevolution of hot-stage microscopy to aid solid-state characterizations of \n\npharmaceutical solids. Thermochimica Acta, V. 324 p. 187-196, 1998. \n\n \n\nWANG, A. J.; LU, Y. P.; SUN, R. X. Recent progress on the fabrication of hollow \n\nmicrospheres. Material science and engeneering A, v. 406, p. 1-6, 2007. \n\n \n\nWON, D-H.; KIM, M-S.; LEE, S.; PARK, J-S.; HWANG, S-J. Improved \n\nphysicochemical characteristics of felodipine solid dispersion particles by \n\nsupercritical anti-solvent precipitation process. International Journal of \n\nPharmaceutics, v. 301, p. 199-208, 2005. \n\n \n\nWURSTER, D. E. 1953. US Patent 2648609."}]}}}